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Introduction
Each year about 70-80 persons in Sweden are diagnosed with ocular melanoma. If enucleation of the affected eye can be avoided, the treatment is then brachytherapy, in which a radioactive plaque is attached to the part of sclera adjacent to the underlying ocular tumor. At the St. Erik Eye Hospital (Stockholm, Sweden), tumors with an apical height below 6 mm are treated with the β-ray emission from 106 Ru. The limited range of β-rays makes them inappropriate for larger tumors due to high proximal sclera doses, where instead discrete 125 I seeds arranged within a collimating metal plaque are used.
The Collaborative Ocular Melanoma Study (COMS) was initiated in 1985 to
evaluate the effectiveness of radiotherapy for ocular melanoma. The COMS study of patients with melanomas of apical height between 2.5 and 10.0 mm found no significant differences in survival rate between patients receiving 125 I brachytherapy and enucleation (1) . However, eye-sparing brachytherapy often retains useful visual acuity and can thus lead to a better life-quality for the patient. COMS has established standardized 125 I gold plaques in different sizes, which are today in widespread clinical practice and are the most frequently used plaque models for eye brachytherapy (2) .
At St. Erik's, custom-made gold plaques are used for 125 I eye brachytherapy.
To the apex of the tumor, a dose of 80 Gy is prescribed, based on TG-43 assumptions. While the COMS system uses silastic seed carriers that establish fixed seed positions and a distinct distance to the sclera, seeds are attached manually to the St. Erik plaque using a thin layer of silicone rubber glue. 125 I seeds, the dose reduction is on the order of 13-14% at 10 mm depth from inner sclera, compared to TG-43 conditions (11, 14) . Another plaque design, the OSU-NAG plaque, has similarities with the St. Erik plaque in that the seeds are manually glued instead of being positioned in a seed carrier (as for COMS plaques) (15, 16) . They differ, however, in that the OSU-NAG plaque displaces the seeds 2 mm from sclera to avoid high dose regions and to reduce the tumor dose gradient.
To compare treatment outcomes and explain side effects from plaque therapy, accurate dosimetry is essential. The report from AAPM TG-129 (2) states that the resulting dose distributions are highly sensitive to the plaque design and the seed model used. This study was initiated to investigate the impact of the plaque and rubber glue heterogeneity of the St. Erik plaque on the dose distribution. Currently, AAPM TG-221 is reviewing the dosimetry of non-COMS plaques for ocular brachytherapy. The dosimetry of this plaque model has not been studied in detail before.
Plaque and seeds
The CCB St. Erik plaque investigated in this study was modeled with diameter 20.0 mm, inner height 5.0 mm and thickness 0.5 mm. The radius of curvature of the concave plaque surface is 11.8 mm. The design of the CCB plaque is shown in Figure 1 . It has been custom-made by a goldsmith to replicate a 106 Ru-plaque of type CCB (Eckert & Ziegler BEBIG GmbH, Berlin, Germany). In addition to the CCB plaque, plaques replicating models CCA, CCC, CIB, COB and CCZ have also been manufactured. The plaque consists of an 18 carat gold alloy. Due to lack of data on the elemental composition, alloy data was taken from the work on gold alloys in jewelry by Raub and Ott (17) . The adopted alloy consisted of 75.0% Au, 15.5% Ag, 9.0% Cu and 0.5% Zn by weight, with a mass density, ρ=15.4 g/cm 3 . The seeds are manually attached to the plaque with rubber glue. As seen in Figure 1 , the glue does not fully cover the seeds. The distance between the outer sclera and the proximal protruding seed edge is uncertain. Due to this uncertainty, the origin of the coordinate system was set at the external rubber glue surface on the plaque's central axis (CAX), and not at the inner sclera as in the COMS reference coordinate system (2).
The seeds are arranged in a predetermined pattern specially designed for the CCB plaque, Figure 2 . The endpoint coordinates for each seed is given in Table 1 The angle φ is the angle between the positive x-axis and a line through origin and the seed center, projected on the x-y plane. The coordinate system is defined with x=0, y=0, z=0 at the external silicone rubber glue surface on the plaque central axis, as indicated in Figure 1 .
Monte Carlo technique
Monte Carlo calculations of dose distributions were performed with the generalpurpose code MCNP5 version 1.51 (20) . All simulations used the default photon cross-section library MCPLIB04, based on ENDF/B-VI.8, which in turn is derived from EPDL97 (21). The decay spectrum for 125 I was taken from TG-43U1 (4). Because of the low energies of photons emitted in the decay of 125 I, charged particle equilibrium was assumed in the scoring voxels and absorbed dose was approximated as collision kerma. This justified the use of the energy deposition tally (F6) for the scoring of absorbed dose rate and collision kerma in the derivation of TG-43 parameters.
Single seed simulations
As a first step, a single I25.S16 seed was modeled in MCNP5 and TG-43 parameters were derived. Using the line-source approximation, the values of the radial dose function, gL(r), anisotropy function, F(r, θ), air-kerma strength, Sk, and dose-rate constant, Λ, were determined.
Dimensions and material compositions were taken from specifications 
Multiseed simulations
To investigate effects of the plaque heterogeneity, two multiseed MC models were created; one with homogeneous water surroundings (homo) and one with Since all seeds were present in the MC model, interseed attenuation was modeled which was not taken into account in the TPS calculations. Interseed effects for different seed models along the CAX of the COMS plaque have been reported to be below 1% (10).
Additional simulations were performed to estimate the effect on the CAX dose rate when the glue layer thickness in the hetero model was varied from 0.0 to 0.5 mm in steps of 0.1 mm.
In all multiseed simulations, the CAX dose rate was estimated using the energy deposition tally F6 with 100 cubical scoring cells (0.02 x 0.02 x 0.02 cm 3 each).
Each simulation was run with 6 x 10 9 starting particles.
Heterogeneity effects were also studied on 3D dose rate distributions. Dose rates were simulated in a rectilinear 3D voxel mesh, superimposed over the geometry, using the FMESH flux tally feature in MCNP5. An FM tally multiplier card was used to transform the FMESH tally to an energy deposition tally, The ratios of the CAX dose rates, simulated in hetero conditions, to that in homo conditions is shown in Figure 3 . The ratio was at a maximum closest to the plaque (104.6% at z = 0.02 mm), decreased to 96.3% at z=10.0 mm, and 93.0% at the most distal point simulated, z=20.0 mm.
The 2D plot in Figure 4 shows the hetero/homo-ratio in a cross-sectional view through the center of the plaque. The 92% isoline approximately coincides with the contour of the eyeball, when the plaque is fitted tightly to it.
Scleral doses were estimated based on the simulation results for hetero conditions. When prescribing 80 Gy to a tumor apex at 7 mm from the external silicone surface, the dose delivered to the apex will be 78.4 Gy (hetero/homoratio 98.0%). The dose to a point 1 mm from the rubber surface (approximately the depth of the inner sclera) will then be 295 Gy. For a tumor apex 12 mm from the external rubber surface, the delivered dose will be 76.8 Gy (hetero/homo-ratio 96.0%) and the dose at 1 mm distance 675 Gy. The dose to a 1 mm 3 cubic voxel centered directly in front of seed 9 (see Figure 2 ) was estimated to 472 Gy -1126 Gy for prescription points at 7 -12 mm from the rubber surface on the plaque's CAX.
Results of the simulations of the CAX dose rates with various thicknesses of silicone rubber are shown in Figure 5 . The results were normalized to the dose rates with a 0.3 mm thick rubber glue layer. Close to the plaque, the relative dose rates differed by several percent, up to 4.3% for the bare plaque (0.0 mm thickness). The differences decreased with distance. From approximately 3.0 mm from the external rubber glue surface, the dose rates were within ±1.0% for all layer thicknesses investigated.
Discussion
In simulations of 10 seeds attached with 0.3 mm silicone rubber to the gold plaque, the dose rate close to the plaque exceeded that in homogeneous water conditions, as predicted by TG-43 based TPS. This is in contrast to the dose modifying effects of the more commonly used COMS plaque, for which studies have shown a hetero/homo-ratio consistently below 1.00, mainly due to attenuation in the silastic seed carrier (11, 14, 23 mm, i.e. with the apex located at least 7 mm from the plaque surface. At this depth, the inaccuracy due to variations in rubber thickness is not likely to be larger than 1%.
In the assembled plaque, the layer of silicone rubber does not fully cover the seeds and the protruding parts of the sources will be in direct contact with sclera. Other plaque designs, as the COMS plaque and the OSU-Nag plaque, displace the seeds to maintain a certain distance to sclera, to reduce the sclera dose and the tumor dose gradient (2, 15) . The protruding sources of the St. Erik plaque make the position of the plaque relative to the sclera uncertain. In reality, there might be a sub-millimeter air-layer between them, displacing the plaque by the same distance. In this study, the seeds and plaque were Giles, UK) was rescaled. Doses to the inner sclera, for a prescribed dose of 85
Gy in the COMS plaque, were estimated to 232 Gy and 508 Gy for tumors with apical heights of 6 mm and 11 mm respectively. This is to be seen as a rough comparison since the plaque designs, the source positions, number of sources and source models differ.
Conclusion
A 125 I eye plaque brachytherapy system for treatment of ocular tumors with apical height larger than 6 mm was studied by means of MC simulations.
When taking the heterogeneities of the plaque and seed fixating glue into account, dose rates along the plaque central axis exceeded the homogeneous water situation by 4.6% close to the plaque, but decreased it by 7.0% at 20.0 mm from the external glue surface. The high dose ratios close to the plaque were attributed mainly the thin glue layer, which allows characteristic X-rays from the gold alloy backing to reach the eyeball.
application did not affect the central axis dose rates by more than 1% at depths greater than 3.0 mm from the external surface of the rubber glue. Close to the plaque, the dose rate was higher in heterogeneous than in homogeneous conditions. This is in contrast to what has been reported for more commonly used eye plaques, demonstrating the importance of investigating the dosimetry of individual systems if outcomes are to be compared in clinical trials or combined in the search for improved dose response data. Drawing of the seed positions in the 20.0 mm diameter CCB plaque. The figure also shows the angle φ, which is used in Table 1 along with the coordinates of each seed. Figure 3 The figure presents the ratio of the dose rates along the CAX of the plaque with the gold alloy backing and rubber glue (hetero) to the dose rate in homogeneous water conditions (homo).
Figure 4
A cross-sectional view through the center of the plaque of the hetero/homoratio, i.e. the ratio of dose rate with gold plaque and rubber present, to the dose rate in homogeneous water conditions. The positions of the plaque (dark gray) and the silicone rubber layer (light gray) have been indicated for guidance Figure 5 MC simulated dose rates along the CAX of the plaque, for varying thicknesses of the silicone rubber layer. The dose rates are normalized to the dose rate for 0.3 mm thickness.
